Cencora Reports Strong Q1 Earnings Amid Market Challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2024
0mins
Should l Buy COR?
Cencora Inc. experienced a price decline of 5.04% as it hit a 5-day low, reflecting market pressures despite strong earnings results.
The company reported a 5.5% revenue growth for Q1 2026, with revenue reaching $85.9 billion, driven by a 5.0% increase in the U.S. Healthcare Solutions segment and a 9.6% rise in the International Healthcare Solutions segment. Additionally, Cencora raised its adjusted operating income growth guidance for fiscal 2026 from 8%-10% to 11.5%-13.5%, primarily due to the completion of the OneOncology acquisition, which is expected to enhance its market position in oncology care.
Despite the strong earnings report, Cencora's stock price fell, indicating a potential sector rotation as the broader market showed mixed signals, with the Nasdaq-100 down 0.24% while the S&P 500 was up 0.12%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COR
Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 372.650
Low
400.00
Averages
415.38
High
440.00
Current: 372.650
Low
400.00
Averages
415.38
High
440.00
About COR
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
TimesSquare Capital Increases ESAB Holdings by 262,850 Shares
- Share Acquisition Details: On February 6, 2026, TimesSquare Capital Management disclosed an increase of 262,850 shares in ESAB during Q4, representing an estimated trade value of $30.08 million, indicating growing confidence in industrial manufacturing and infrastructure spending.
- Asset Allocation Shift: This acquisition raised ESAB's share to 1.61% of TimesSquare's 13F assets under management, reflecting the firm's strategic focus on this sector and enhancing ESAB's market position.
- Market Performance Analysis: As of February 5, 2026, ESAB shares were priced at $127.90, up 5.3% over the past year but trailing the S&P 500 by 6.8 percentage points, suggesting a cautious market outlook on its future growth.
- Industry Outlook: As a leading provider of welding and cutting solutions with approximately $2.8 billion in annual revenue, ESAB is expected to benefit from ongoing infrastructure investments and manufacturing growth, making it sensitive to economic cycles and government spending priorities.
See More
TimesSquare Capital Increases ESAB Stake by $30 Million
- Share Acquisition Details: On February 6, 2026, TimesSquare Capital Management disclosed the purchase of 262,850 shares of ESAB, representing an estimated trade size of $30.08 million, indicating growing confidence in industrial manufacturing and infrastructure spending.
- Value Increase: Following this transaction, the total value of ESAB shares held rose to $107.15 million, reflecting a $29.35 million increase at quarter-end, showcasing the dual impact of purchasing activity and stock price movements.
- Portfolio Allocation: ESAB accounts for 1.61% of TimesSquare's assets under management, and while it does not rank among the top five holdings, the 38% increase in position suggests a bullish outlook on sectors related to construction and energy projects.
- Industry Outlook: As a leading provider of welding and cutting solutions with approximately $2.8 billion in annual revenue, ESAB is well-positioned to benefit from ongoing infrastructure investments, making it an attractive option for investors sensitive to economic cycles.
See More
Cencora and Covetrus Enter Definitive Merger Agreement
- Merger Overview: Cencora and Covetrus have entered into a definitive agreement to merge MWI Animal Health with Covetrus, creating a comprehensive animal health platform, with the transaction valuing MWI at an enterprise value of $3.5 billion, exceeding Cencora's current book value, indicating strong market optimism about the merger.
- Cash and Equity Structure: Upon closing, Cencora will receive $1.25 billion in upfront cash, $800 million in preferred equity, and $1.45 billion in common equity, resulting in a 34.3% non-controlling stake in the combined company, thereby enhancing its market position in the animal health sector.
- Financial Guidance Reaffirmed: Cencora reaffirmed its fiscal 2026 financial guidance, projecting operating income growth between 11.5% and 13.5%, indicating that the company can maintain robust growth while integrating OneOncology, which boosts investor confidence.
- Strategic Market Implications: This merger not only enhances Cencora's asset value and market share but also provides a stronger competitive edge in the rapidly growing animal health market, expected to drive future business growth and innovation.
See More
Cencora Prices $3 Billion in Senior Notes Offering
- Financing Scale: Cencora successfully priced $1.5 billion in senior notes across five different maturities, demonstrating strong capital market capabilities despite a slight market reaction with shares down 0.90%.
- Note Rates: The notes range from 3.950% to 5.650%, reflecting market assessments of the company's credit risk, with higher rates potentially increasing future financial costs and impacting profitability.
- Maturity Structure: The notes have maturities ranging from 2029 to 2056, providing a flexible financing structure that helps Cencora meet capital needs in the coming years while supporting its business expansion strategy.
- Market Expectations: The offering is expected to close on February 13, 2026, with Cencora projecting an 11.5%-13.5% operating income growth for 2026, indicating confidence in future performance despite current stock price challenges.
See More
Cencora Prices $1.5 Billion Senior Notes Offering
- Financing Scale: Cencora announced a $1.5 billion offering of five different senior notes with varying maturities, including 3.950% notes due in 2029, 4.250% notes due in 2030, 4.600% notes due in 2033, 4.900% notes due in 2036, and 5.650% notes due in 2056, demonstrating the company's robust capital market financing capabilities.
- Use of Proceeds: The net proceeds from this offering will be used to repay amounts outstanding under Cencora's 364-Day Term Credit Agreement dated January 12, 2026, which was utilized to partially fund Cencora's acquisition of OneOncology, indicating the company's strategic focus on financial integration post-acquisition.
- Underwriting Team: The offering is being managed by a consortium of leading banks including Citigroup, J.P. Morgan, BofA Securities, and Wells Fargo Securities, reflecting strong market confidence in Cencora and its significant position within the industry.
- Compliance Statement: Cencora emphasized that this offering does not constitute an offer to sell or solicit offers to buy the notes, and sales may be unlawful in certain states or jurisdictions, highlighting the company's commitment to compliance with securities laws.
See More
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
TimesSquare Capital Increases ESAB Holdings by 262,850 Shares
- Share Acquisition Details: On February 6, 2026, TimesSquare Capital Management disclosed an increase of 262,850 shares in ESAB during Q4, representing an estimated trade value of $30.08 million, indicating growing confidence in industrial manufacturing and infrastructure spending.
- Asset Allocation Shift: This acquisition raised ESAB's share to 1.61% of TimesSquare's 13F assets under management, reflecting the firm's strategic focus on this sector and enhancing ESAB's market position.
- Market Performance Analysis: As of February 5, 2026, ESAB shares were priced at $127.90, up 5.3% over the past year but trailing the S&P 500 by 6.8 percentage points, suggesting a cautious market outlook on its future growth.
- Industry Outlook: As a leading provider of welding and cutting solutions with approximately $2.8 billion in annual revenue, ESAB is expected to benefit from ongoing infrastructure investments and manufacturing growth, making it sensitive to economic cycles and government spending priorities.
See More
TimesSquare Capital Increases ESAB Stake by $30 Million
- Share Acquisition Details: On February 6, 2026, TimesSquare Capital Management disclosed the purchase of 262,850 shares of ESAB, representing an estimated trade size of $30.08 million, indicating growing confidence in industrial manufacturing and infrastructure spending.
- Value Increase: Following this transaction, the total value of ESAB shares held rose to $107.15 million, reflecting a $29.35 million increase at quarter-end, showcasing the dual impact of purchasing activity and stock price movements.
- Portfolio Allocation: ESAB accounts for 1.61% of TimesSquare's assets under management, and while it does not rank among the top five holdings, the 38% increase in position suggests a bullish outlook on sectors related to construction and energy projects.
- Industry Outlook: As a leading provider of welding and cutting solutions with approximately $2.8 billion in annual revenue, ESAB is well-positioned to benefit from ongoing infrastructure investments, making it an attractive option for investors sensitive to economic cycles.
See More
Cencora and Covetrus Enter Definitive Merger Agreement
- Merger Overview: Cencora and Covetrus have entered into a definitive agreement to merge MWI Animal Health with Covetrus, creating a comprehensive animal health platform, with the transaction valuing MWI at an enterprise value of $3.5 billion, exceeding Cencora's current book value, indicating strong market optimism about the merger.
- Cash and Equity Structure: Upon closing, Cencora will receive $1.25 billion in upfront cash, $800 million in preferred equity, and $1.45 billion in common equity, resulting in a 34.3% non-controlling stake in the combined company, thereby enhancing its market position in the animal health sector.
- Financial Guidance Reaffirmed: Cencora reaffirmed its fiscal 2026 financial guidance, projecting operating income growth between 11.5% and 13.5%, indicating that the company can maintain robust growth while integrating OneOncology, which boosts investor confidence.
- Strategic Market Implications: This merger not only enhances Cencora's asset value and market share but also provides a stronger competitive edge in the rapidly growing animal health market, expected to drive future business growth and innovation.
See More
Cencora Prices $3 Billion in Senior Notes Offering
- Financing Scale: Cencora successfully priced $1.5 billion in senior notes across five different maturities, demonstrating strong capital market capabilities despite a slight market reaction with shares down 0.90%.
- Note Rates: The notes range from 3.950% to 5.650%, reflecting market assessments of the company's credit risk, with higher rates potentially increasing future financial costs and impacting profitability.
- Maturity Structure: The notes have maturities ranging from 2029 to 2056, providing a flexible financing structure that helps Cencora meet capital needs in the coming years while supporting its business expansion strategy.
- Market Expectations: The offering is expected to close on February 13, 2026, with Cencora projecting an 11.5%-13.5% operating income growth for 2026, indicating confidence in future performance despite current stock price challenges.
See More
Cencora Prices $1.5 Billion Senior Notes Offering
- Financing Scale: Cencora announced a $1.5 billion offering of five different senior notes with varying maturities, including 3.950% notes due in 2029, 4.250% notes due in 2030, 4.600% notes due in 2033, 4.900% notes due in 2036, and 5.650% notes due in 2056, demonstrating the company's robust capital market financing capabilities.
- Use of Proceeds: The net proceeds from this offering will be used to repay amounts outstanding under Cencora's 364-Day Term Credit Agreement dated January 12, 2026, which was utilized to partially fund Cencora's acquisition of OneOncology, indicating the company's strategic focus on financial integration post-acquisition.
- Underwriting Team: The offering is being managed by a consortium of leading banks including Citigroup, J.P. Morgan, BofA Securities, and Wells Fargo Securities, reflecting strong market confidence in Cencora and its significant position within the industry.
- Compliance Statement: Cencora emphasized that this offering does not constitute an offer to sell or solicit offers to buy the notes, and sales may be unlawful in certain states or jurisdictions, highlighting the company's commitment to compliance with securities laws.
See More
